Obesity Cohort Bichat Louis Mourier
COBILOM
Cohorte Obésité Bichat LOuis Mourier
1 other identifier
observational
360
1 country
1
Brief Summary
Obesity prevalence rapidly increased in the past decades in French population with multiple health consequences responsible for excess mortality. In the same period of time, the number of bariatric procedures have developed exponentially. Despite its great efficacy on weight loss but also on resolution of comorbidities, bariatric surgery is not without risks. Our hypothesis is that a better understanding of the physio-pathological consequences of obesity and bariatric surgery, notably on the gastrointestinal tract, may allow to improve the treatment of obesity and to find alternatives to bariatric surgery. The main objective of this cohort study is to systematize the collection and the conservation of biological samples (blood, stomach, liver, intestine, adipose tissue) obtained during bariatric surgery, in obese subjects undergoing surgery (including sleeve gastrectomy, Roux-en-Y gastric bypass, or revisional intervention for complication or weight regain) in the University Hospital group of Paris Nord Val de Seine (HYPNVS). The main projects that will build on this cohort will cover the physiopathology of obesity and its consequences, notably in the field of gastrointestinal tract including: modification of gastro-intestinal plasticity in severe obesity and after bariatric surgery and alterations of absorption of nutriments (lipids, proteins, carbohydrates) induced by obesity and bariatric surgery. The inclusion in this project of obese subjects before surgery, or lean or obese subjects after surgery will allow to distinguish the impact of weight loss and surgery on gastrointestinal remodeling. This cohort will also allow to characterize stomach and intestinal proteome in severe obesity and to precise the influence of tissue inflammation on metabolic disorders associated with obesity.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Feb 2018
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 16, 2018
CompletedFirst Submitted
Initial submission to the registry
March 6, 2018
CompletedFirst Posted
Study publicly available on registry
May 29, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 3, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
March 3, 2026
CompletedMarch 31, 2026
March 1, 2026
8 years
March 6, 2018
March 26, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
number of biological samples collected
liver stomach and intestin samples will be performed during surgery for usual care. Adiposes tissues and blood samples will be performed for reseach, on the surgical site
during surgery
Secondary Outcomes (4)
modifications of gastro-intestinal plasticity induces by obesity and bariatric surgery
samples collected during surgery
alterations of absroption and metabolism of nutriments induced by obesity and bariatric surgery
samples collected during surgery
gastric and intestinal proteome
samples collected during surgery
tissue inflammation and fibrosis
samples collected during surgery
Eligibility Criteria
severe obese subjects operated for bariatric surgery or reoperated for complication
You may qualify if:
- severe obese subject with BMI above35 kg/m2, age above 18 ans who accept to participate
- candidate for bariatric surgery according to HAS criteria
- who will undergo either sleeve gastrectomy or gastric bypass
- or who undergoesa revisional surgery for a complication of bariatric surgery
- or who undergoes arevisional sugery fir insufficient weight loss
- covered by an health insurance
You may not qualify if:
- psychiatric disease or undertanding disorder
- alchool abuse or other addiction
- organ failure (including liver, heart or kidney)
- chronic life-threatening illness
- inflamatory disease or immunosuppressive treatment
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Hôpital Lousi Mourier (HUPNVS)
Colombes, Île-de-France Region, 92700, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 6, 2018
First Posted
May 29, 2018
Study Start
February 16, 2018
Primary Completion
March 3, 2026
Study Completion
March 3, 2026
Last Updated
March 31, 2026
Record last verified: 2026-03